, /PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP 宣布，购买了 ICON PLC (NASDAQ: ICLR) 普通股的投资者，时间范围为 2023 年 7 月 27 日至 2024 年 10 月 23 日（包括这两个日期）（“诉讼期间”），可以在 2025 年 4 月 11 日之前申请成为 ICON 集体诉讼的首席原告。该集体诉讼标题为 Shing v. ICON plc，案号 25-cv-00763 (E.D.N.Y.)，指控 ICON 及其某些高管违反了 1934 年证券交易法。
如果您遭受了重大损失并希望担任 ICON 集体诉讼的首席原告，请在此提供您的信息：
https://www.rgrdlaw.com/cases-icon-plc-class-action-lawsuit-iclr.html
您也可以通过拨打 800/449-4900 或发送电子邮件至 [email protected] 联系 Robbins Geller 的律师 J.C. Sanchez 或 Jennifer N. Caringal。
案件指控：ICON 是一家临床研究组织（“CRO”）。
ICON 集体诉讼指控被告在诉讼期间内发表了虚假和/或误导性陈述，和/或未能披露以下事实：(i) ICON 因客户成本削减措施和其他广泛的资金限制而遭受了重大业务损失；(ii) ICON 所声称的功能服务提供（“FSP”）和混合模型产品不足以保护 ICON 免受重大市场下滑的负面影响；(iii) 在诉讼期间，ICON 从生物技术客户收到的提案请求在很大程度上被用作价格发现工具，因此并不代表潜在客户需求；(iv) ICON 的客户取消了合同，限制或减少了合作，推迟了临床试验工作，和/或未能与 ICON 签订新的合同以进行额外的临床试验工作，且在现有项目结束（或计划结束）后，历史费率未能恢复（2024 年）；(v) ICON 的两个最大客户正在将其 CRO 供应商多元化，逐渐减少对 ICON 的依赖；(vi) 由于上述原因，ICON 报告的净新业务奖励和账单比率严重误导了客户对 ICON 服务的需求；(vii) 因此，ICON 的业绩显著低于在诉讼期间发布的 2024 年收入和每股收益指引，而该指引缺乏合理的事实依据。
2024 年 10 月 23 日，ICON 报告了其 2024 财年第三季度的财务结果，披露 ICON 仅产生了 20.3 亿美元的季度收入，显示出意外的 “收入短缺”，显著低于共识预期的 21.3 亿美元，差距超过 1 亿美元。ICON 进一步透露，其季度净新业务赢得额从前一季度的 26 亿美元下降至本季度的 23 亿美元，ICON 的账单比率也从前一季度的 1.22 下降至 1.15。在随后的电话会议中，ICON 首席执行官、被告 Stephen Cutler 透露，由于持续的成本控制措施，ICON 的两家大型制药客户已大幅减少即将进行的 FSP 试验工作，他表示这将继续对 ICON 的财务表现产生负面影响。此消息发布后，ICON 普通股的价格在两个交易日内下跌超过 20%。
原告由 Robbins Geller 代表，该公司在起诉投资者集体诉讼方面拥有 丰富的经验，包括涉及金融欺诈的案件。您可以 点击此处 查看投诉副本。
首席原告流程：1995 年《私人证券诉讼改革法》允许在诉讼期间购买 ICON 普通股的任何投资者申请成为 ICON 集体诉讼的首席原告。首席原告通常是寻求救济的潜在集体中财务利益最大的动议者，并且是典型且适合的集体成员。首席原告代表所有其他集体成员指导 ICON 集体诉讼。首席原告可以选择其希望的律师事务所来进行 ICON 集体诉讼。投资者分享 ICON 集体诉讼未来潜在赔偿的能力并不依赖于担任首席原告。
关于 ROBBINS GELLER：Robbins Geller Rudman &amp; Dowd LLP 是全球领先的法律事务所之一，代表投资者处理证券欺诈案件。我们的公司在过去十年中有六年在 ISS 证券集体诉讼服务排名中名列第一，为投资者争取了最多的经济救济。我们为投资者在与证券相关的集体诉讼中追回了 66 亿美元的赔偿——比过去四年中任何其他律师事务所多出超过 22 亿美元。Robbins Geller 拥有 200 名律师，设有 10 个办公室，是全球最大的原告律师事务所之一，公司的律师获得了历史上许多最大的证券集体诉讼赔偿，包括历史上最大的证券集体诉讼赔偿——72 亿美元——在 In re Enron Corp. Sec. Litig. 案中。有关更多信息，请访问以下页面：
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
过去的结果并不保证未来的结果。
服务可能由我们任何办公室的律师提供。
联系方式：
Robbins Geller Rudman &amp; Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
来源 Robbins Geller Rudman &amp; Dowd LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjE1Jk5ld3NJdGVtSWQ9TEEyMDI3NyZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTUxMDAwUFJfTkVXU19VU1BSX19fX19MQTIwMjc3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjE1Jk5ld3NJdGVtSWQ9TEEyMDI3NyZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTUxMDAwUFJfTkVXU19VU1BSX19fX19MQTIwMjc3"/>

ICLR

Robbins Geller Rudman & Dowd LLP 宣布，2023 年 7 月 27 日至 2024 年 10 月 23 日期间遭受重大损失的 ICON PLC (NASDAQ: ICLR) 投资者可以寻求领导集体诉讼。该诉讼指控 ICON 及其高管违反证券交易法，发布关于业务表现和客户需求的误导性声明。在 2024 年 10 月 23 日报告了显著的收入短缺后，ICON 的股价下跌超过 20%。有意的投资者必须在 2025 年 4 月 11 日前申请，以被考虑为主要原告

, /PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP announces that purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and October 23, 2024, both dates inclusive (the &#34;Class Period&#34;), have until April 11, 2025 to seek appointment as lead plaintiff of the ICON class action lawsuit. Captioned Shing v. ICON plc, No. 25-cv-00763 (E.D.N.Y.), the ICON class action lawsuit charges ICON and certain of ICON's top executive officers with violations of the Securities Exchange Act of 1934.
<div class="lb-trans">, /PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP 宣布，购买了 ICON PLC (NASDAQ: ICLR) 普通股的投资者，时间范围为 2023 年 7 月 27 日至 2024 年 10 月 23 日（包括这两个日期）（“诉讼期间”），可以在 2025 年 4 月 11 日之前申请成为 ICON 集体诉讼的首席原告。该集体诉讼标题为 Shing v. ICON plc，案号 25-cv-00763 (E.D.N.Y.)，指控 ICON 及其某些高管违反了 1934 年证券交易法。
</div>If you suffered substantial losses and wish to serve as lead plaintiff of the ICON class action lawsuit, please provide your information here:
<div class="lb-trans">如果您遭受了重大损失并希望担任 ICON 集体诉讼的首席原告，请在此提供您的信息：
</div>https://www.rgrdlaw.com/cases-icon-plc-class-action-lawsuit-iclr.html
<div class="lb-trans">https://www.rgrdlaw.com/cases-icon-plc-class-action-lawsuit-iclr.html
</div>You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].
<div class="lb-trans">您也可以通过拨打 800/449-4900 或发送电子邮件至 [email protected] 联系 Robbins Geller 的律师 J.C. Sanchez 或 Jennifer N. Caringal。
</div>CASE ALLEGATIONS: ICON is a clinical research organization (&#34;CRO&#34;).
<div class="lb-trans">案件指控：ICON 是一家临床研究组织（“CRO”）。
</div>The ICON class action lawsuit alleges that defendants throughout the Class period made false and/or misleading statements and/or failed to disclose that: (i) ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting ICON's client base; (ii) ICON's purported Functional Service Provision (&#34;FSP&#34;) and hybrid model offerings were insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (iv) ICON's customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (v) ICON's two largest customers were diversifying their CRO providers away from ICON; (vi) as a result of the above, ICON's reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON's services; and (vii) consequently, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the Class Period and such guidance lacked a reasonable factual basis.
<div class="lb-trans">ICON 集体诉讼指控被告在诉讼期间内发表了虚假和/或误导性陈述，和/或未能披露以下事实：(i) ICON 因客户成本削减措施和其他广泛的资金限制而遭受了重大业务损失；(ii) ICON 所声称的功能服务提供（“FSP”）和混合模型产品不足以保护 ICON 免受重大市场下滑的负面影响；(iii) 在诉讼期间，ICON 从生物技术客户收到的提案请求在很大程度上被用作价格发现工具，因此并不代表潜在客户需求；(iv) ICON 的客户取消了合同，限制或减少了合作，推迟了临床试验工作，和/或未能与 ICON 签订新的合同以进行额外的临床试验工作，且在现有项目结束（或计划结束）后，历史费率未能恢复（2024 年）；(v) ICON 的两个最大客户正在将其 CRO 供应商多元化，逐渐减少对 ICON 的依赖；(vi) 由于上述原因，ICON 报告的净新业务奖励和账单比率严重误导了客户对 ICON 服务的需求；(vii) 因此，ICON 的业绩显著低于在诉讼期间发布的 2024 年收入和每股收益指引，而该指引缺乏合理的事实依据。
</div>On October 23, 2024, ICON reported financial results for its third fiscal quarter of 2024, disclosing that ICON had generated quarterly revenues of just $2.03 billion, revealing a surprise &#34;revenue shortfall&#34; that significantly missed consensus estimates of $2.13 billion by more than $100 million. ICON further revealed that its quarterly net new business wins had declined sequentially to $2.3 billion during the quarter from $2.6 billion in the prior quarter and that ICON's book-to-bill ratio fell sequentially to 1.15, down from 1.22 in the prior quarter. During the corresponding conference call, ICON CEO, defendant Stephen Cutler, revealed that two of ICON's large pharmaceutical customers had materially curtailed upcoming FSP trial work due to ongoing cost containment measures, which he stated would continue to negatively impact ICON's financial performance going forward. On this news, the price of ICON ordinary shares fell more than 20% over two trading sessions.
<div class="lb-trans">2024 年 10 月 23 日，ICON 报告了其 2024 财年第三季度的财务结果，披露 ICON 仅产生了 20.3 亿美元的季度收入，显示出意外的 “收入短缺”，显著低于共识预期的 21.3 亿美元，差距超过 1 亿美元。ICON 进一步透露，其季度净新业务赢得额从前一季度的 26 亿美元下降至本季度的 23 亿美元，ICON 的账单比率也从前一季度的 1.22 下降至 1.15。在随后的电话会议中，ICON 首席执行官、被告 Stephen Cutler 透露，由于持续的成本控制措施，ICON 的两家大型制药客户已大幅减少即将进行的 FSP 试验工作，他表示这将继续对 ICON 的财务表现产生负面影响。此消息发布后，ICON 普通股的价格在两个交易日内下跌超过 20%。
</div>The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.
<div class="lb-trans">原告由 Robbins Geller 代表，该公司在起诉投资者集体诉讼方面拥有 丰富的经验，包括涉及金融欺诈的案件。您可以 点击此处 查看投诉副本。
</div>THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased ICON ordinary shares during the Class Period to seek appointment as lead plaintiff in the ICON class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the ICON class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the ICON class action lawsuit. An investor's ability to share in any potential future recovery of the ICON class action lawsuit is not dependent upon serving as lead plaintiff.
<div class="lb-trans">首席原告流程：1995 年《私人证券诉讼改革法》允许在诉讼期间购买 ICON 普通股的任何投资者申请成为 ICON 集体诉讼的首席原告。首席原告通常是寻求救济的潜在集体中财务利益最大的动议者，并且是典型且适合的集体成员。首席原告代表所有其他集体成员指导 ICON 集体诉讼。首席原告可以选择其希望的律师事务所来进行 ICON 集体诉讼。投资者分享 ICON 集体诉讼未来潜在赔偿的能力并不依赖于担任首席原告。
</div>ABOUT ROBBINS GELLER: Robbins Geller Rudman &amp; Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
<div class="lb-trans">关于 ROBBINS GELLER：Robbins Geller Rudman &amp; Dowd LLP 是全球领先的法律事务所之一，代表投资者处理证券欺诈案件。我们的公司在过去十年中有六年在 ISS 证券集体诉讼服务排名中名列第一，为投资者争取了最多的经济救济。我们为投资者在与证券相关的集体诉讼中追回了 66 亿美元的赔偿——比过去四年中任何其他律师事务所多出超过 22 亿美元。Robbins Geller 拥有 200 名律师，设有 10 个办公室，是全球最大的原告律师事务所之一，公司的律师获得了历史上许多最大的证券集体诉讼赔偿，包括历史上最大的证券集体诉讼赔偿——72 亿美元——在 In re Enron Corp. Sec. Litig. 案中。有关更多信息，请访问以下页面：
</div>https://www.rgrdlaw.com/services-litigation-securities-fraud.html
<div class="lb-trans">https://www.rgrdlaw.com/services-litigation-securities-fraud.html
</div>Past results do not guarantee future outcomes.
<div class="lb-trans">过去的结果并不保证未来的结果。
</div>Services may be performed by attorneys in any of our offices.
<div class="lb-trans">服务可能由我们任何办公室的律师提供。
</div>Contact:
<div class="lb-trans">联系方式：
</div>Robbins Geller Rudman &amp; Dowd LLP
<div class="lb-trans">Robbins Geller Rudman &amp; Dowd LLP
</div>J.C. Sanchez, Jennifer N. Caringal
<div class="lb-trans">J.C. Sanchez, Jennifer N. Caringal
</div>655 W. Broadway, Suite 1900, San Diego, CA 92101
<div class="lb-trans">655 W. Broadway, Suite 1900, San Diego, CA 92101
</div>800-449-4900
<div class="lb-trans">800-449-4900
</div>[email protected]
<div class="lb-trans">[email protected]
</div>SOURCE Robbins Geller Rudman &amp; Dowd LLP
<div class="lb-trans">来源 Robbins Geller Rudman &amp; Dowd LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjE1Jk5ld3NJdGVtSWQ9TEEyMDI3NyZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTUxMDAwUFJfTkVXU19VU1BSX19fX19MQTIwMjc3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA20277&amp;Transmission_Id=202502151000PR_NEWS_USPR_____LA20277&amp;DateId=20250215"/>

ICLR 投资者通知：ICON PLC 的投资者如果遭受重大损失，有机会主导集体诉讼